In last trading session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) saw 1.07 million shares changing hands with its beta currently measuring 0.66. Company’s recent per share price level of $9.76 trading at $0.5 or 5.40% at ring of the bell on the day assigns it a market valuation of $570.76M. That closing price of PHAT’s stock is at a discount of -74.39% from its 52-week high price of $17.02 and is indicating a premium of 37.81% from its 52-week low price of $6.07. Taking a look at company’s average trading volume volume of 891.29K if we extend that period to 3-months.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Upright in the green during last session for gaining 5.40%, in the last five days PHAT remained trading in the green while hitting it’s week-highest on Thursday, 05/02/24 when the stock touched $9.76 price level, adding 0.91% to its value on the day. Phathom Pharmaceuticals Inc’s shares saw a change of 6.90% in year-to-date performance and have moved 7.25% in past 5-day. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) showed a performance of -1.01% in past 30-days.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Statistics highlight that Phathom Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 4.95% of value to its shares in past 6 months, showing an annual growth rate of -66.80% while that of industry is 12.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 6,470.40% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.05M for the same. And 7 analysts are in estimates of company making revenue of 6.07M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.06% during past 5 years.
PHAT Dividends
Phathom Pharmaceuticals Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
